Evolus, Inc.
Business
Evolus, Inc. is a global performance beauty company that develops and commercializes injectable products for the medical aesthetics market. The company's primary offerings are Jeuveau®, a proprietary botulinum toxin type A formulation for frown lines, and Evolysse™, a collection of injectable hyaluronic acid gels for wrinkles, folds, and facial volume. Products are sold directly to licensed aesthetic practitioners in a cash-pay model in the United States, Canada, European markets, Australia, and other territories, with manufacturing outsourced to third-party suppliers.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cost, Product and Service [Extensible Enumeration] | — | — | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-07-31 | FY 2023 2023-12-31 | FY 2023 2023-07-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 54 | 87 | — | 63 | — | |
| Accounts receivable, net | 55 | 48 | — | 31 | — | |
| Inventories | 27 | 12 | — | 11 | — | |
| Prepaid expenses | 4 | 3 | — | 6 | — | |
| Other current assets | 4 | 1 | — | 2 | — | |
| Total current assets | 143 | 151 | — | 112 | — | |
| Property and equipment, net | 5 | 3 | — | 2 | — | |
| Operating lease right-of-use assets | 7 | 7 | 3 | 6 | 5 | |
| Intangible assets, net | 48 | 49 | — | 47 | — | |
| Goodwill | 21 | 21 | — | 21 | — | |
| Other assets | 1 | 858,000 | — | 409,000 | — | |
| Total assets | 226 | 233 | — | 189 | — | |
| Accounts payable | 23 | 9 | — | 4 | — | |
| Accrued expenses | 36 | 41 | — | 34 | — | |
| Current portion of operating lease liabilities | 3 | 2 | — | 1 | — | |
| Current portion of contingent royalty obligation payable to Evolus Founders | 13 | 11 | — | 9 | — | |
| Current portion of contingent milestone payment | 1 | 0 | — | — | — | |
| Total current liabilities | 75 | 63 | — | 48 | — | |
| Long-term portion of operating lease liabilities | 6 | 7 | — | 5 | — | |
| Long-term portion of contingent royalty obligation payable to Evolus Founders | 20 | 34 | — | — | — | |
| Long-term portion of term loan, net of discount and issuance costs | 146 | 122 | — | 120 | — | |
| Long-term portion of contingent milestone payment | 2 | 2 | — | 0 | — | |
| Deferred tax liability | 28,000 | 6,000 | — | 27,000 | — | |
| Total liabilities | 249 | 227 | — | 210 | — | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | 0 | 0 | — | 0 | — | |
| Common Stock, $0.00001 par value; 100,000,000 shares authorized; 65,008,183 and 63,497,548 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,000 | 1,000 | — | 1,000 | — | |
| Additional paid-in capital | 638 | 616 | — | 539 | — | |
| Accumulated other comprehensive loss | −156,000 | −905,000 | — | −427,000 | — | |
| Accumulated deficit | −661 | −609 | — | −559 | — | |
| Total stockholders equity (deficit) | −23 | 6 | — | −21 | — | |
| Total liabilities and stockholders equity (deficit) | 226 | 233 | — | 189 | — | |
| Common stock, shares, issued (in shares) | 65 | 63 | — | 58 | — | |
| Common stock, shares, outstanding (in shares) | 65 | 63 | — | 58 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 8 | 5 | 5 | 4 | — | |
| Stock-based compensation | 21 | 22 | 16 | 11 | 10 | |
| Provision for credit losses and inventory | 7 | 2 | 1 | — | — | |
| Amortization of operating lease right-of-use assets | 1 | 723,000 | 734,000 | 775,000 | 692,000 | |
| Amortization of debt discount and issuance costs | 1 | 1 | 1 | 1 | 941,000 | |
| Deferred income taxes | 21,000 | −21,000 | 5,000 | −18,000 | 15,000 | |
| Revaluation of contingent royalty obligation payable to Evolus Founders | −6 | 7 | 4 | 6 | 6 | |
| Non-cash in-process research and development expense | 0 | 0 | 4 | 0 | — | |
| Other adjustments to operating activities | 967,000 | 36,000 | 0 | — | — | |
| Inventories | −11 | 3 | 4 | −11 | −3 | |
| Accounts receivable | −12 | −20 | −10 | −9 | −6 | |
| Prepaid expenses | −355,000 | 2 | −2 | 1 | −254,000 | |
| Accounts payable | 10 | 391,000 | −1 | 968,000 | −787,000 | |
| Accrued expenses | −6 | 7 | 9 | −5 | 21 | |
| Accrued litigation settlement | 0 | 0 | −5 | −15 | — | |
| Operating lease liabilities | −758,000 | −716,000 | −907,000 | — | — | |
| Other operating assets | −2 | 706,000 | −864,000 | — | 0 | |
| Net cash used in operating activities | −42 | −18 | −34 | −85 | −33 | |
| Purchases of property and equipment | −3 | −1 | −473,000 | −2 | −393,000 | |
| Additions to capitalized software | −5 | −3 | −1 | −1 | −577,000 | |
| Net cash used in investing activities | −8 | −5 | −2 | −3 | 4 | |
| Payment of contingent royalty obligation to Evolus Founders | −6 | −7 | −6 | −4 | −3 | |
| Proceeds from issuance and modification of debt instruments | 25 | 0 | 50 | — | — | |
| Payments for debt modification fees and debt issuance costs | −3 | 0 | −46,000 | — | — | |
| Proceeds from follow-on offering | 0 | 51 | 0 | 0 | — | |
| Payments for offering costs | 0 | −248,000 | 0 | 0 | −214,000 | |
| Issuance of common stock in connection with incentive equity plan | 1 | 5 | 231,000 | 539,000 | 655,000 | |
| Payment of finance lease obligations | −15,000 | 0 | 0 | — | — | |
| Tax withholding paid on behalf of employees for net share settlement | 0 | −990,000 | −7,000 | 0 | — | |
| Net cash provided by financing activities | 17 | 47 | 45 | −4 | 73 | |
| Effect of exchange rates on cash and cash equivalents | 254,000 | −478,000 | −90,000 | −337,000 | 0 | |
| Net increase (decrease) in cash and cash equivalents | −33 | 24 | 9 | −92 | 44 | |
| Cash paid for interest | 15 | 18 | 13 | 8 | 138,000 | |
| Cash paid for income taxes | 1 | 235,000 | 117,000 | 76,000 | 14,000 | |
| Capital expenditures included in accounts payable and accrued expenses | 695,000 | 252,000 | 43,000 | 0 | 10,000 | |
| Issuance of common stock in connection with Symatese Europe Agreement | 0 | 0 | 1 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Evolus, Inc.'s CIK number?
Evolus, Inc.'s SEC CIK number is 0001570562 (1570562). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Evolus, Inc.'s SEC filings?
All of Evolus, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Evolus, Inc. last report earnings?
Evolus, Inc. (EOLS) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001570562-26-000064). This is Evolus, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Evolus, Inc.'s most recent earnings 8-K?
Evolus, Inc.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001570562-26-000064. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Evolus, Inc.'s latest earnings 8-K →
Look up any company's CIK number →